FR 127519

Drug Profile

FR 127519

Latest Information Update: 24 Aug 2001

Price : $50

At a glance

  • Originator Fujisawa
  • Class Anti-inflammatories
  • Mechanism of Action Cholecystokinin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pancreatitis

Most Recent Events

  • 24 Aug 2001 No-Development-Reported for Pancreatitis in Japan (Unknown route)
  • 23 Jun 1998 Commercial data has been reviewed by Fujisawa
  • 30 Jan 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top